The development of effective treatments in this patient population is impeded by the lack of clarity regarding potential underlying mechanisms, as well as the variety of heterogeneous endotypes of severe, steroid-resistant asthma. Although the condition is often linked with non-eosinophilic asthma endotypes 4,5 such as neutrophilic asthma, other findings suggest the involvement of persistent eosinophilic inflammation in severe disease. 6 “This heterogeneity of disease and likely involvement of different underlying immunological, inflammatory, and molecular mechanisms in different subtypes of severe, steroid-resistant asthma has hampered the development of effective therapies,” Dr Hansbro and colleagues wrote in a review recently published in Immunological Reviews. 7
Although peak plasma prednisolone levels are somewhat lower after administration of Deltacortril Gastro-resistant Tablets and absorption is delayed, total absorption and bioavailability are the same as after plain prednisolone. Prednisolone shows dose dependent pharmacokinetics, with an increase in dose leading to an increase in volume of distribution and plasma clearance. The degree of plasma protein binding determines the distribution and clearance of free, pharmacologically active drug. Reduced doses are necessary in patients with hypoalbuminaemia.